# A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

> **NCT04118127** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 73 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** 2mg conventional tablet, once-weekly tablets

## Key facts

- **NCT ID:** NCT04118127
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2021-02-16
- **Final completion:** 2021-03-03
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04118127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04118127, "A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04118127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*